Results 141 to 150 of about 3,003 (174)

Hirudin and Hirulog: Advances in antithrombotic therapy

Perspectives in Drug Discovery and Design, 1994
Over the past two decades, advances in the prevention and treatment of coronary artery disease, e.g., coronary angioplasty and coronary thrombolysis, have been coupled with the need for improved antithrombotic therapy to prevent acute, life-threatening thrombotic complications.
openaire   +1 more source

Combination of Antibiotic Treatment with the Thrombin Inhibitor Recombinant Hirudin for the Therapy of Experimental Klebsiella pneumoniae Sepsis

Thrombosis and Haemostasis, 1994
SummaryRats which were infected with the gramnegative pathogen Klebsiella pneumoniae develop disseminated intravascular coagulation (DIC), multi-organ failure (MOF) and finally die in a septic shock. We investigated the therapeutic effect of antibiotic (tobramycin) treatment combined with the infusion of the highly specific thrombin inhibitor rec ...
G, Dickneite, J, Czech
openaire   +2 more sources

Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. II. Adjunctive Therapy with r-Hirudin

Journal of Cardiovascular Pharmacology, 1994
We examined the effectiveness of the direct-acting thrombin inhibitor, recombinant hirudin (r-hirudin), for prevention of coronary rethrombosis after thrombolysis with recombinant tissue plasminogen activator (rt-PA) in a canine model of coronary artery thrombosis.
W E, Rote, D X, Mu, E R, Bates, M A, Nedelman, B R, Lucchesi   +4 more
openaire   +2 more sources

Novel Strategy of Gene Delivery System Based on Dendrimer Loaded Recombinant Hirudine Plasmid for Thrombus Targeting Therapy

Molecular Pharmaceutics, 2019
This study proposed a new nonviral gene delivery system for thrombus targeting therapy based on PEGlyation polyamides dendrimer (PAMAM) modified with RGDyC to condense the pDNA with recombinant hirudine (rHV) gene (RGDyC-rHV-EGFP). The RGDyC-mPEG-PAMAM was synthesized and characterized by 1H NMR, PAMAM/pDNA was characterized by particle size, zeta ...
Junjie Chen, Yanping Lu, Ying Cheng, Rui Ma, Jiafeng Zou, Hongyue Zheng, Ruwei Wang, Zhihong Zhu, Fanzhu Li   +8 more
openaire   +2 more sources

Monitoring Anticoagulant Therapy by Activated Partial Thromboplastin Time: Hirudin Assessment

Thrombosis and Haemostasis, 1994
SummaryBackground. Recombinant hirudin (RH) is a new anticoagulant for prophylaxis and treatment of venous and arterial thrombosis. To which extent the activated partial thromboplastin time (APTT) is suitable for monitoring of RH has not been properly evaluated.
Nurmohamed, M T, Berckmans, R J, Morriën-Salomons, W M, Berends, F, Hommes, D W, Rijnierse, J J, Sturk, A   +6 more
openaire   +5 more sources

[Hirudin therapy and blood coagulability].

Kardiologiia, 1992
The changes in blood coagulative properties, which occur in the treatment with medical leeches, were studied in 57 patients with coronary heart, rheumatic and chronic pulmonary diseases. Hirudin therapy was established to affect blood coagulation. The leech salina penetrated into the skin wound to block hemostasis. Having entered the circulating blood,
G S, Isakhanian, K S, Tumasian, Z E, Barsegian, L S, Mkrtchian, A K, Karapetian, N G, Fldzhian   +5 more
openaire   +1 more source

Hirudin: Pharmakologie und Therapie

1999
Der medizinische Blutegel (Hirudo medicinalis), ein blutsaugender Parasit, eroffnet durch einen Y-formigen Bis der 3 bezahnten Kiefer Blutgefase in der Unterhautregion seiner Opfer. Durch die Benetzung der Wundrander mit dem Sekret der kranialen Speicheldrusen des Blutegels wird die Wunde offengehalten und gleichzeitig das gesaugte Blut antikoaguliert.
openaire   +1 more source

Therapy and Monitoring of Heparin-Induced Thrombocytopenia Type II in Critically Ill Patients During Continuous Venovenous Hemodiafiltration: Comparison of aPTT and Ecarin Clotting Time for Monitoring of r-Hirudin Therapy

Journal of Intensive Care Medicine, 2002
We conducted a survey of therapy, complications, and monitoring of heparin-induced thrombocytopenia (HIT) type II in critically ill patients during continuous venovenous hemodiafiltration (CVVHDF). We also compared activated partial thromboplastin time (aPTT) and ecarin clotting time (ECT) for monitoring recombinant (r)-hirudin ...
Elke Muhl, Hans-Joachim Siemens, Peter Kujath, Hans-Peter Bruch   +3 more
openaire   +1 more source

Does Antithrombotic Therapy Influence Residual Thrombus After Thrombolysis of Platelet-Rich Thrombus?

Circulation, 1996
Background Thrombolysis to normal flow in patients with acute myocardial infarction preserves left ventricular function and decreases mortality. Failure of early reperfusion, reocclusion, or residual thrombus may be due to concurrent activation of the platelet-coagulation system.
J S, Mruk, P, Zoldhelyi, M W, Webster, M, Heras, D E, Grill, D R, Holmes, V, Fuster, J H, Chesebro   +7 more
openaire   +2 more sources

[Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin].

Presse medicale (Paris, France : 1983), 1996
Heparin-induced thrombocytopenia is an uncommon and severe complication of heparin therapy. Both venous and arterial thromboembolic events can occur, requiring withdrawal of the heparin therapy. When anticoagulant therapy is mandatory, recombinant hirudin can be used.We used recombinant hirudin (HBW 023) in 6 patients with heparin induced ...
F, Schiele, A, Vuillemenot, T, Mouhat, Y, Kieffer, T, Anguenot, Y, Bernard, J P, Bassand   +6 more
openaire   +1 more source